- Home
- SRZN vs INMB Comparison
SRZN vs INMB Comparison
Compare SRZN & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- INMB
- Stock Information
- Founded
- SRZN 2015
- INMB 2015
- Country
- SRZN United States
- INMB United States
- Employees
- SRZN N/A
- INMB N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- SRZN Health Care
- INMB Health Care
- Exchange
- SRZN Nasdaq
- INMB Nasdaq
- Market Cap
- SRZN 72.8M
- INMB 68.9M
- IPO Year
- SRZN N/A
- INMB 2019
- Fundamental
- Price
- SRZN $8.71
- INMB $2.31
- Analyst Decision
- SRZN Strong Buy
- INMB Buy
- Analyst Count
- SRZN 2
- INMB 4
- Target Price
- SRZN $38.50
- INMB $9.53
- AVG Volume (30 Days)
- SRZN 22.6K
- INMB 6.9M
- Earning Date
- SRZN 08-11-2025
- INMB 07-31-2025
- Dividend Yield
- SRZN N/A
- INMB N/A
- EPS Growth
- SRZN N/A
- INMB N/A
- EPS
- SRZN N/A
- INMB N/A
- Revenue
- SRZN $11,638,000.00
- INMB $50,000.00
- Revenue This Year
- SRZN N/A
- INMB $82.14
- Revenue Next Year
- SRZN N/A
- INMB $28,750.98
- P/E Ratio
- SRZN N/A
- INMB N/A
- Revenue Growth
- SRZN N/A
- INMB N/A
- 52 Week Low
- SRZN $5.90
- INMB $1.89
- 52 Week High
- SRZN $18.17
- INMB $11.64
- Technical
- Relative Strength Index (RSI)
- SRZN 47.45
- INMB 26.84
- Support Level
- SRZN $8.00
- INMB $2.22
- Resistance Level
- SRZN $8.94
- INMB $2.49
- Average True Range (ATR)
- SRZN 0.72
- INMB 0.94
- MACD
- SRZN -0.07
- INMB -0.24
- Stochastic Oscillator
- SRZN 27.14
- INMB 4.31
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.